STCube Q1 2026: Losses Continue, Nelmastobart Enters Phase 2 for NSCLC

Consolidated revenue of KRW 1.36bn (down 24.7% YoY from KRW 1.81bn)
Operating loss of KRW 7.31bn (vs KRW 5.17bn loss in Q1 2025)
Net loss of KRW 6.75bn (vs KRW 5.17bn loss in Q1 2025)
R&D expenses of KRW 4.20bn (308% of revenue)
Cash and short-term financial instruments of KRW 62.66bn
Nelmastobart (BTN1A1) Phase 2 IND approved for NSCLC; first patient dosed in Jan 2026
Metastatic colorectal cancer Phase 1b/2 advanced to Phase 2 dosing
No share buyback, cancellation, or dividend plans